This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Joep C. Defesche, PhD; Kees L. Pricker, MD; Michael R. Hayden, PhD, MD; Bram E. van der Ende, PhD; John J. P. Kastelein, PhD, MD

Arch Intern Med. 1993;153(20):2349-2356.

Abstract
Background
Familial defective apolipoprotein B-100 is caused by a substitution of adenine for guanine in exon 26 of the gene coding for apolipoprotein B, which results in the substitution of glutamine for arginine in the putative low-density lipoprotein—receptor binding domain of the mature protein. This amino acid substitution diminishes the binding capacity of the low-density lipiprotein particle for the low-density lipoprotein receptor, which in turn leads to an increase in levels of plasma total and low-density lipoprotein cholesterol.

Methods
To identify carriers of this mutation by means of molecular biology techniques in a large cohort of Dutch patients living in the Netherlands and in Canada with primary hypercholesterolemia, to establish the frequency of the disorder, and to investigate its clinical signs and symptoms and the response to cholesterol-lowering therapy.

Results
A total of 1248 patients were screened, and the mutation was found in 18 patients who were initially all diagnosed as having familial hypercholesterolemia. Ten of 18 patients had tendon xanthomas or an arcus cornealis or both, and eight of 18 patients had angina or other evidence of coronary artery disease.

Conclusions
The disorder was clinically indistinguishable from familial hypercholesterolemia in terms of physical characteristics and lipoprotein measures. Response to lipid-lowering therapy with β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors was similar to that reported in patients with familial hypercholesterolemia. The mutation was associated with a similar haplotype, which was also reported in other patients of Western European descent with familial defective apolipoprotein B100. This strongly suggests that the mutation has a common chromosomal background that originated in Western Europe.

(Arch Intern Med. 1993;153:2349-2356)

Author Affiliations
From the Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, Amsterdam, the Netherlands (Drs Defesche, Pricker, and Kastelein); Department of Medical Genetics, University of British Columbia, Vancouver (Dr Hayden); and Department of Clinical Chemistry, Slotervaart Hospital, Amsterdam (Dr van der Ende).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
Holmes et al.
Clin. Chem. 2005;51:2067-2073.
ABSTRACT | FULL TEXT  

Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review
Austin et al.
Am J Epidemiol 2004;160:421-429.
ABSTRACT | FULL TEXT  

High frequency of the ApoB-100 R3500Q mutation in Bulgarian hypercholesterolaemic subjects
Horvath et al.
J. Med. Genet. 2001;38:536-540.
FULL TEXT  

Compound Heterozygous Familial Hypercholesterolemia and Familial Defective Apolipoprotein B-100 Produce Exaggerated Hypercholesterolemia
Tai et al.
Clin. Chem. 2001;47:438-443.
ABSTRACT | FULL TEXT  

Genetic Localization to Chromosome 1p32 of the Third Locus for Familial Hypercholesterolemia in a Utah Kindred
Hunt et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:1089-1093.
ABSTRACT | FULL TEXT  

Flow Cytometric Assessment of LDL Ligand Function for Detection of Heterozygous Familial Defective Apolipoprotein B-100
Raungaard et al.
Clin. Chem. 2000;46:224-233.
ABSTRACT | FULL TEXT  

Differences in the Phenotype Between Children With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia
Pimstone et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:826-833.
ABSTRACT | FULL TEXT  

Phenotypic Variation in Patients Heterozygous for Familial Defective Apolipoprotein B (FDB) in Three European Countries
Hansen et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:741-747.
ABSTRACT | FULL TEXT  

Differences in the Phenotypic Characteristics of Subjects With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia
Miserez and Keller
Arterioscler. Thromb. Vasc. Bio. 1995;15:1719-1729.
ABSTRACT | FULL TEXT